Cargando…

Patient Satisfaction with a Dedicated Infusion Pump for Subcutaneous Treprostinil to Treat Pulmonary Arterial Hypertension

Background and Objectives: Parenteral prostacyclins are crucial in the pharmacological treatment of pulmonary arterial hypertension (PAH). Indeed, subcutaneous administration of treprostinil has been associated with considerable clinical and hemodynamic improvement, right-sided heart reverse remodel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waligóra, Marcin, Żuławinska, Barbara, Tomaszewski, Michał, Roset, Pere, Kopeć, Grzegorz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058864/ https://www.ncbi.nlm.nih.gov/pubmed/36983605 http://dx.doi.org/10.3390/jpm13030423

Ejemplares similares

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil
por: Jansa, Pavel, et al.
Publicado: (2023)

An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
por: Kurzyna, Marcin, et al.
Publicado: (2017)

Treprostinil for pulmonary hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2008)

Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2018)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
por: McSweeney, Julia, et al.
Publicado: (2023)

Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
por: Desole, Susanna, et al.
Publicado: (2018)

Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina
por: Lescano, Adrián, et al.
Publicado: (2022)

Long-term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertension—procedural safety and system-related complications
por: Steringer-Mascherbauer, Regina, et al.
Publicado: (2020)

ECG Markers of Hemodynamic Improvement in Patients with Pulmonary Hypertension
por: Waligóra, Marcin, et al.
Publicado: (2018)

Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases
por: Kavgacı, Akif, et al.
Publicado: (2023)

Corrigendum to “ECG Markers of Hemodynamic Improvement in Patients with Pulmonary Hypertension”
por: Waligóra, Marcin, et al.
Publicado: (2018)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

Inhaled treprostinil and pulmonary arterial hypertension
por: Nadler, Samuel T, et al.
Publicado: (2010)

Pediatric subcutaneous treprostinil site maintenance and pain control strategies from the Pediatric Pulmonary Hypertension Network
por: Jackson, Emma O., et al.
Publicado: (2021)

Case report: Stepwise transition from subcutaneous treprostinil to epoprostenol in high-risk pulmonary arterial hypertension
por: Mori, Ana Laura, et al.
Publicado: (2021)

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension
por: Richter, Manuel J., et al.
Publicado: (2020)

Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
por: Kamp, Jan C., et al.
Publicado: (2021)

Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension
por: Chen, Hubert, et al.
Publicado: (2013)

Changes in Inflammatory Markers in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty
por: Magoń, Wojciech, et al.
Publicado: (2022)

Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension
por: Khan, Akram, et al.
Publicado: (2022)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

Clinical response to calcium channel blockers in a hemodynamically unstable patient with reactive idiopathic pulmonary arterial hypertension
por: Kopec, Grzegorz, et al.
Publicado: (2017)

Virtual Histology to Evaluate Mechanisms of Pulmonary Artery Lumen Enlargement in Response to Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension
por: Magoń, Wojciech, et al.
Publicado: (2020)

Extended Precordial T Wave Inversions Are Associated with Right Ventricular Enlargement and Poor Prognosis in Pulmonary Hypertension
por: Waligóra, Marcin, et al.
Publicado: (2021)

Overexpression of PD-1 on Peripheral Blood Lymphocytes in Patients with Idiopathic Pulmonary Arterial Hypertension and Its Association with High Viral Loads of Epstein-Barr Virus and Poor Clinical Parameters
por: Tomaszewski, Michał, et al.
Publicado: (2020)

Unexpected Acceleration in Treprostinil Delivery Administered by a Lenus Pro® Implantable Pump in Two Patients Treated for Pulmonary Arterial Hypertension
por: Kopp, Garance, et al.
Publicado: (2020)

Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
por: Ivy, D. Dunbar, et al.
Publicado: (2019)

Prognostic role of traditional cardiovascular risk factors in patients with idiopathic pulmonary arterial hypertension
por: Jonas, Kamil, et al.
Publicado: (2018)

The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease
por: Bajwa, Abubakr A., et al.
Publicado: (2017)

8% Capsaicin Patch as Analgesia for Severe Treprostinil Infusion Site Pain
por: Light, Allison, et al.
Publicado: (2017)

Role of the Immune System Elements in Pulmonary Arterial Hypertension
por: Tomaszewski, Michał, et al.
Publicado: (2021)

Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
por: Mirza, Shireen, et al.
Publicado: (2012)

Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review
por: Buckley, Mitchell S, et al.
Publicado: (2014)

Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
por: Pugliese, Steven C, et al.
Publicado: (2016)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
por: Furukawa, Asuka, et al.
Publicado: (2017)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
por: Oriaku, Ifeoma, et al.
Publicado: (2020)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
por: Kuwana, Masataka, et al.
Publicado: (2023)

Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy
por: Adachi, Shiro, et al.
Publicado: (2022)

Low-density lipoprotein cholesterol and survival in pulmonary arterial hypertension
por: Kopeć, Grzegorz, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lr3l84qofi7c9380csini218rg